40. Hepatocellular Carcinoma

  1. John WD McDonald Professor of Medicine3,
  2. Andrew K Burroughs Professor of Hepatology Consultant Physician/Hepatologist4,
  3. Brian G Feagan Professor of Medicine3 and
  4. M Brian Fennerty Professor of Medicine5
  1. Massimo Colombo1 and
  2. Massimo Iavarone2

Published Online: 22 JUL 2010

DOI: 10.1002/9781444314403.ch40

Evidence-Based Gastroenterology and Hepatology, Third Edition

Evidence-Based Gastroenterology and Hepatology, Third Edition

How to Cite

Colombo, M. and Iavarone, M. (2010) Hepatocellular Carcinoma, in Evidence-Based Gastroenterology and Hepatology, Third Edition (eds J. W. McDonald, A. K. Burroughs, B. G. Feagan and M. B. Fennerty), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444314403.ch40

Editor Information

  1. 3

    Robarts Clinical Trials, Robarts Research Unit, University of Western Ontario, London, Ontario, Canada

  2. 4

    The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, and University College London, London, UK

  3. 5

    Oregon Health and Science University, Division of Gastroenterology and Hepatology, Portland, Oregon, USA

Author Information

  1. 1

    Department of Medicine, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy

  2. 2

    Department of Medicine, First Division of Gastroenterology, Fondazione IRCCS Maggiore Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy

Publication History

  1. Published Online: 22 JUL 2010
  2. Published Print: 10 SEP 2010

ISBN Information

Print ISBN: 9781405181938

Online ISBN: 9781444314403

SEARCH

Keywords:

  • Treatment of patients with cirrhosis and HCC;
  • Treatment of patients with normal livers;
  • Hepatocellular carcinoma (HCC);
  • Population to be screened;
  • hepatitis B virus (HBV) and hepatitis C virus (HCV);
  • serum alfafetoprotein (AFP) levels;
  • The AASLD indicates surveillance for non-cirrhotic HBV-carriers with signs of liver inflammation;
  • des-gamma carboxy-prothrombin (DCP);
  • Is liver-related mortality reduced by screening?;
  • Is surveillance in patients with cirrhosis cost-effective?

Summary

This chapter contains sections titled:

  • Introduction

  • Early diagnosis

  • Population to be screened

  • Screening tests

  • The recall policy

  • Treatment of patients with cirrhosis and HCC

  • Intermediate HCC

  • Advanced HCC

  • End-stage HCC

  • Treatment of patients with normal livers

  • Acknowledgement

  • References